Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891666 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1107406 | 0.80 | MAPT (0.39) | SMN1; SMN2SLC6A3KDM4EMEN1ALDH1A1 | |
| SCHEMBL13771831 | 0.79 | PPARD (0.38) | SMN1; SMN2SLC6A3KDM4EMEN1ALDH1A1 | |
| SCHEMBL12742377 | 0.70 | CA1 (0.40) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL1398205 | 0.69 | — | — | |
| SCHEMBL243107 | 0.68 | — | — | |
| SCHEMBL128429 | 0.68 | — | — | |
| SCHEMBL13141021 | 0.67 | — | — | |
| SCHEMBL18673935 | 0.67 | SLC6A3 (0.43) | SMN1; SMN2SLC6A3KDM4EMEN1ALDH1A1 | |
| SCHEMBL13142435 | 0.67 | SLC6A3 (0.43) | SLC6A3ALDH1A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | SMN1; SMN2 4603/4885SLC6A3 2874/4885KDM4E 2426/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | SMN1; SMN2 4647/4885SLC6A3 2729/4885KDM4E 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.